Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nephros (NEPH) EPS (Weighted Average and Diluted) (2022 - 2025)

Nephros (NEPH) has 9 years of EPS (Weighted Average and Diluted) data on record, last reported at $0.03 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 50.0% year-over-year to $0.03; the TTM value through Sep 2025 reached $0.14, up 255.56%, while the annual FY2024 figure was $0.01, 106.67% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.03 in Q3 2025 per NEPH's latest filing, up from $0.02 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.05 in Q1 2025 and bottomed at -$0.31 in Q3 2022.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$0.04, with a median of -$0.02 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): increased 25.0% in 2024, then surged 350.0% in 2025.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.11 in 2022, then skyrocketed by 45.45% to -$0.06 in 2023, then soared by 166.67% to $0.04 in 2024, then dropped by 25.0% to $0.03 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were $0.03 in Q3 2025, $0.02 in Q2 2025, and $0.05 in Q1 2025.